These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 27035909)

  • 1. [Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT)].
    Papamichail DG; Exadaktylou PE; Chatzipavlidou VD
    Hell J Nucl Med; 2016; 19(1):75-82. PubMed ID: 27035909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; de Herder WW; Krenning EP
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors.
    Giovacchini G; Nicolas G; Forrer F
    Anticancer Agents Med Chem; 2012 Jun; 12(5):526-42. PubMed ID: 22292758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
    Bergsma H; van Vliet EI; Teunissen JJ; Kam BL; de Herder WW; Peeters RP; Krenning EP; Kwekkeboom DJ
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):867-81. PubMed ID: 23582925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors.
    Krenning EP; Teunissen JJ; Valkema R; deHerder WW; deJong M; Kwekkeboom DJ
    J Endocrinol Invest; 2005; 28(11 Suppl International):146-50. PubMed ID: 16625865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors.
    Taïeb D; Garrigue P; Bardiès M; Abdullah AE; Pacak K
    PET Clin; 2015 Oct; 10(4):477-86. PubMed ID: 26384594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
    Bodei L; Pepe G; Paganelli G
    Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.
    Van Essen M; Krenning EP; De Jong M; Valkema R; Kwekkeboom DJ
    Acta Oncol; 2007; 46(6):723-34. PubMed ID: 17653893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.
    Hörsch D; Ezziddin S; Haug A; Gratz KF; Dunkelmann S; Miederer M; Schreckenberger M; Krause BJ; Bengel FM; Bartenstein P; Biersack HJ; Pöpperl G; Baum RP
    Eur J Cancer; 2016 May; 58():41-51. PubMed ID: 26943056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
    Kwekkeboom DJ; Krenning EP
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polish experience in Peptide receptor radionuclide therapy.
    Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
    Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview and Current Status of Peptide Receptor Radionuclide Therapy.
    Bushnell DL; Bodeker KL
    Surg Oncol Clin N Am; 2020 Apr; 29(2):317-326. PubMed ID: 32151363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide-receptor radionuclide therapy for endocrine tumors.
    van Essen M; Krenning EP; Kam BL; de Jong M; Valkema R; Kwekkeboom DJ
    Nat Rev Endocrinol; 2009 Jul; 5(7):382-93. PubMed ID: 19488074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide Receptor Radionuclide Therapy with
    Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
    J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-emitting radionuclides for peptide receptor radionuclide therapy.
    Parus JL; Mikolajczak R
    Curr Top Med Chem; 2012; 12(23):2686-93. PubMed ID: 23339764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Somatostatin receptor endoradiotherapy of neuroendocrine tumors: experience in Hungarian patients].
    Reismann P; Kender Z; Dabasi G; Sréter L; Rácz K; Igaz P
    Orv Hetil; 2011 Mar; 152(10):392-7. PubMed ID: 21354955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.